⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
NEULANDLAB - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.7
| Stock Code | NEULANDLAB | Market Cap | 15,906 Cr. | Current Price | 12,398 ₹ | High / Low | 19,748 ₹ |
| Stock P/E | 89.2 | Book Value | 1,257 ₹ | Dividend Yield | 0.10 % | ROCE | 18.7 % |
| ROE | 14.8 % | Face Value | 10.0 ₹ | DMA 50 | 13,422 ₹ | DMA 200 | 14,007 ₹ |
| Chg in FII Hold | 0.30 % | Chg in DII Hold | 1.17 % | PAT Qtr | 40.4 Cr. | PAT Prev Qtr | 96.5 Cr. |
| RSI | 42.1 | MACD | -317 | Volume | 23,777 | Avg Vol 1Wk | 36,508 |
| Low price | 10,060 ₹ | High price | 19,748 ₹ | PEG Ratio | 1.88 | Debt to equity | 0.16 |
| 52w Index | 24.1 % | Qtr Profit Var | -29.2 % | EPS | 139 ₹ | Industry PE | 27.6 |
📊 Financials
- Revenue & Profitability: PAT fell sharply from ₹96.5 Cr. to ₹40.4 Cr. (-29.2%), showing earnings pressure. EPS at ₹139 is decent but volatile.
- Margins & Returns: ROCE (18.7%) and ROE (14.8%) are moderate, reflecting average efficiency.
- Debt: Debt-to-equity ratio of 0.16 indicates low leverage, ensuring financial stability.
- Cash Flow: Stable due to low debt, though profitability fluctuations affect consistency.
💹 Valuation
- P/E Ratio: 89.2 vs Industry PE of 27.6 → Significantly overvalued compared to peers.
- P/B Ratio: ~9.87 (Price ₹12,398 / Book Value ₹1,257) → Expensive on book value basis.
- PEG Ratio: 1.88 → Growth moderately justifies valuation but still stretched.
- Intrinsic Value: Current price trades above fair value, limiting upside potential.
🏢 Business Model & Competitive Advantage
- Neuland Labs operates in pharmaceuticals and APIs, focusing on niche molecules and global clients.
- Competitive advantage lies in R&D capabilities, regulatory approvals, and export-driven business.
- Dividend yield of 0.10% is negligible, reflecting reinvestment focus.
📈 Entry Zone & Long-Term Guidance
- Entry Zone: Attractive near ₹11,000–11,800 range (closer to DMA 200 at ₹14,007 and 52W low of ₹10,060).
- Long-Term Holding: Suitable for investors seeking exposure to pharma growth, but accumulation should be cautious due to stretched valuations and earnings volatility.
✅ Positive
- Low debt-to-equity ratio (0.16) ensures financial safety.
- Strong presence in niche pharmaceutical APIs.
- FII holdings increased (+0.30%) and DII holdings increased (+1.17%), showing institutional confidence.
⚠️ Limitation
- High P/E ratio (89.2) compared to industry average.
- Dividend yield is negligible (0.10%).
- Quarterly profit decline (-29.2%) signals near-term weakness.
📉 Company Negative News
- PAT dropped significantly compared to previous quarter.
- MACD at -317 indicates strong bearish technical momentum.
- RSI at 42.1 shows weak sentiment.
📈 Company Positive News
- Institutional holdings increased, signaling confidence.
- Debt remains low, providing financial stability.
- EPS at ₹139 reflects decent earnings power despite volatility.
🏭 Industry
- Pharmaceutical industry benefits from global demand, regulatory approvals, and healthcare expansion.
- Industry PE at 27.6 suggests peers trade at lower valuations, making Neuland Labs relatively expensive.
🔎 Conclusion
- Neuland Labs is financially stable with niche pharma expertise and institutional support.
- However, high valuations, weak profitability, and negligible dividend yield limit aggressive upside.
- Best strategy: Accumulate cautiously near ₹11,000–11,800 range for long-term holding, focusing on pharma sector growth while avoiding aggressive buying at current levels.